Abstracts tagged "methotrexate (MTX)"

Abstract Number: 2354 • 2019 ACR/ARP Annual Meeting
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Helen Gosselt¹, Maxime Verhoeven ², Maurits de Rotte ³, Saskia Pluijm ⁴, Gerrit Jansen ⁵, Janneke Tekstra ², Sandra Heil ⁶, Floris Lafeber ², Mieke Hazes* ⁷ and Robert de Jonge* ⁸, ¹Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands and Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Amsterdam, Netherlands, ²UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ³Amsterdam UMC, Amsterdam Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Prinses Máxima Centre for Paediatric Oncology, Department of Paediatric Oncology Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Amsterdam UMC, VU Medical Center, Amsterdam Rheumatology and immunology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁶Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁸Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Methotrexate (MTX) constitutes first-line therapy in rheumatoid arthritis (RA). However, up to 40% of RA patients do not benefit from MTX therapy. To restrain…
Abstract Number: 386 • 2019 ACR/ARP Annual Meeting
Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain
Sarah Ringsted¹ and Marcia Friedman ¹, ¹Oregon Health and Science University, Portland, OR
Background/Purpose: Idiopathic granulomatous mastitis (IGM) is an inflammatory breast disease occurring primarily in young to middle-aged women (1, 2). IGM typically presents with a tender,…
Abstract Number: 2357 • 2019 ACR/ARP Annual Meeting
Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
Daniel Solomon¹, Nina Paynter ², Anna Rutherford ², Robert Glynn ³, Jean MacFadyen ⁴, Fengxin Lu ⁴, Chang Xu ⁴, Elizabeth Karlson ⁴ and Paul Ridker ², ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Harvard Medical School - Boston, MA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Liver test abnormalities are known to predict liver pathology in patients using methotrexate (MTX). Monitoring guidelines for MTX suggest frequent assessment of liver tests…
Abstract Number: 505 • 2019 ACR/ARP Annual Meeting
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Takeshi Suzuki¹, Marina Uchida ², Shoshi Shinagawa ², Machiko Mizushima ³, Takayasu Ando ³, Yutaka Gotou ³, Tomohiko Shibata ² and Kimito Kawahata ⁴, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁴Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: It has been recommended that tapering csDMARDs should be considered if a patient is in persistent remission. However, methods for tapering csDMARDs, including MTX,…
Abstract Number: 2363 • 2019 ACR/ARP Annual Meeting
Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
Eugenio Chamizo Carmona¹, Carmen carrasco-Cubero ², Sara María Rojas Herrera ¹, María Eugenia Gonzalez Naranjo ², Juan José Aznar Sanchez ³, Raul Veroz Gonzalez ¹, Pedro Dorado ² and Adrian LLerena Ruiz ², ¹Hospital de Mérida, Mérida, Spain, ²CHU de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida
Background/Purpose: Rheumatoid arthritis (RA) produces joint destruction, functional deterioration, comorbidity and premature death. The best results are achieved with an early start of a treat-to-target…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
Abstract Number: 2364 • 2019 ACR/ARP Annual Meeting
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
Yoshihiko Hoshida¹, Shiro Ohshima ², Yukihiko Saeki ³, Masao Katayama ⁴, Tomoya Miyamura ⁵, Atsuahi Hashimoto ⁶, Shinji Higa ⁷, Hisaji Oshima ⁸, Masato Yagita ⁹, Yasushi Hiramatsu ¹⁰, Norie Yoshikawa ¹¹, Akiko Mitsuo ¹², Akira Okamoto ¹³, Noriyuki Chiba ¹⁴, Takao Sugiyama ¹⁵, Shouhei Nagaoka ¹⁶, Shoji Sugii ¹⁷, Keigo Setoguchi ¹⁸, Asami Abe ¹⁹, Toshiaki Sugaya ²⁰, Masahiro Koseto ²¹, Yasuo Kunugiza ²², Ryousuke Yoshihara ²³, Shinichiro Tsunoda ²⁴, Tomoaki Fujisaki ²⁵, Hiroshi Furukawa ²⁶, Kazuyoshi Saito ²⁷, Kiyoshi Matsui ²⁸, Yasuhiko Tomita ²⁹ and Shigeto Tohma ³⁰, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, ²NHO Osaka Minami Medical Canter, Kawachinagano, Osaka, Japan, ³NHO Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, ⁴National Hospital Organization Nagoya Medical Center, Nagoya, Japan, ⁵NHO Kyusyu Medical Center, Fukuoka, Japan, ⁶NHO Sagamihara Hospital, Sagamihara, Japan, ⁷Osaka Second Police Hospital, Osaka, Japan, ⁸NHO Tokyo Medical Hospital, Tokyo, Japan, ⁹Kitano Hospital, Osaka, Japan, ¹⁰Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, ¹¹NHO Miyakonojo Medical Center, Miyakonojo, Miyazaki, Japan, ¹²NHO Disaster Medical Center, Tokyo, Tokyo, Japan, ¹³National Hospital Organization HImeji Medical Center, Himeji, Hyogo, Japan, ¹⁴National Hospital Organization Morioka Medical Center, Morioka, Iwate, Japan, ¹⁵NHO Shimoshizu Hospital, Chiba, Chiba, Japan, ¹⁶Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, ¹⁷Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, ¹⁸Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, ¹⁹Niigata Rheumatic Center, Shibata, Niigata, Japan, ²⁰Fuchu Hospital, Izumi, Osaka, Japan, ²¹Nippon Life Hospital, Osaka, Osaka, Japan, ²²JCHO Hoshigaoka Medical Center, Katano, Osaka, Japan, ²³Hyogo Prefecture Kakogawa Hospital, Kakogawa, Hyogo, Japan, ²⁴Sumitomo Hospital, osaka, Osaka, Japan, ²⁵Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan, ²⁶Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ²⁷University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²⁹International University of health and welfare, Narita, Chiba, Japan, ³⁰National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) remains as a major problem to resolve among the patients with rheumatoid arthritis (RA). During few decades, rheumatic therapy has dramatically…
Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
John A. Albert¹, Tony Hosey ² and Brian LaMoreaux ², ¹Rheumatic Disease Center, Milwaukee, IL, ²Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Jesus Tornero¹, Mercedes Alperi-López ², Ivan Castellvi ³, Juan José de Agustín de Oro ⁴, Alejandro Escudero ⁵, Rosario Garcia-Vicuña ⁶, Miguel Angel González-Gay ⁷, Cristina Hidalgo ⁸, Esteban Rubio ⁹, Raimon Sanmarti ¹⁰, Núria Casamira ¹¹ and Jaime Calvo-Alen ¹², ¹Hospital de Guadalajara, Guadalajara, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Medical Department, Gebro Pharma S.A., Barcelona, Spain, ¹²Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Alain Sánchez-Rodríguez¹, Citlallyc Josefina Gómez-Ruiz ², Abril Montes-Yanes ² and Gabriel Medrano-Ramírez ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting
Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Mojca Frank-Bertoncelj¹, Oliver Distler ², Tim Killeen ³, Kenneth Kwok ⁴, Lisy Wang ⁵, Caroline Ospelt ¹ and Adrian Ciurea ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Pfizer AG, Zürich, Switzerland, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Thierry Dervieux¹, Joel Kremer ², Kelley Brady ¹, Chihiro Takahashi ³, Tsutomu Takeuchi ⁴ and Yuko Kaneko ⁵, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Keio University Hospital Division of Rheumatology, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
Philip J. Mease¹, Dafna D. Gladman², David H. Collier³, Christopher T. Ritchlin⁴, Philip S. Helliwell⁵, Lyrica Liu⁶, Gregory J. Kricorian³ and James B. Chung³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Leeds, Leeds, United Kingdom, ⁶Amgen Inc., South San Francisco, CA
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].